Effects of antihypertensive drugs on soluble (pro)renin receptor in hypertensive patients: open-label parallel-group controlled study

Effects of antihypertensive drugs on soluble (pro)renin receptor in hypertensive patients: open-label parallel-group controlled study - Effects of antihypertensive drugs on soluble (pro)renin receptor

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006342

Enrollment

2000

Registered

2011-11-01

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Renin-angiotensin system (RAS) blocker group: During 1-2 months of wash-out period, discontinue previously prescribed RAS blockers [angiotensin II receptor blocker (ARB), angiotensin converting enzyme

120/85 mmHg, &lt

140/90 mmHg in elderlies, age above 65 year-old, &lt

130/80 mmHg in patients with diabetes mellitus, chronic kidney disease or old myocardial infarction, &lt

140/90 mmHg patients with cerebrovascular disease, according to hypertension treatment guideline 2009, established by the Japanese Society of Hypertension. To achieve the target blood pressure, gradu

140/90 mmHg patients with cerebrovascular disease, accordin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient who fulfills the diagnostic criteria of hypertension 2. Patient who has been signed the consent form after sufficiently informed and fully understood the study

Exclusion criteria

Exclusion criteria: 1. Patient with chronic kidney disease (CKD) stage 4 or 5 2. Patient whom director of the study disqualified

Design outcomes

Primary

Measure	Time frame
Blood and urine prorenin and soluble (pro)renin receptor	—

Secondary

Measure	Time frame
1. Blood tests: biochemical measurements, hormones, oxidative stress markers, inflammatory markers, renin 2. Urine tests: pH, albumin/creatinine, hormones, oxidative stress markers, renin 3. Imaging tests: X-rays, CT, MRI, echography 4. Physiological tests: ECG, flow-mediated dilataion(FMD), cardio-anke vascular index(CAVI), augmentaion index(AI), ankle-brachial index(ABI), 24 hours ambulatory blood pressure monitoring(ABPM), visceral/subcutaneous fat ratio measurement	—

Measure

Time frame

1. Blood tests: biochemical measurements, hormones, oxidative stress markers, inflammatory markers, renin 2. Urine tests: pH, albumin/creatinine, hormones, oxidative stress markers, renin 3. Imaging tests: X-rays, CT, MRI, echography 4. Physiological tests: ECG, flow-mediated dilataion(FMD), cardio-anke vascular index(CAVI), augmentaion index(AI), ankle-brachial index(ABI), 24 hours ambulatory blood pressure monitoring(ABPM), visceral/subcutaneous fat ratio measurement

—

Countries

Japan

Contacts

Public ContactKanako Bokuda

Tokyo Women's Medical University Department of medicine II

kanakobkd@endm.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026